Overweight or Obesity Clinical Trial
Official title:
Strategies for Improving the Quality of Life of Pre-senior and Senior Populations Based on Precision Nutrition (Proyecto Nutriprecisión)
Verified date | March 2021 |
Source | Clinica Universidad de Navarra, Universidad de Navarra |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The number and proportion of people aged 60 years old and over is increasing worldwide. Ageing is characterized by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death. This deterioration is the primary risk factor for major chronic diseases including diabetes, cardiovascular disease, and neurodegenerative disorders. The incidence of chronic conditions frequently rises sharply with age, after long exposure to unhealthful lifestyles involving the consumption of unhealthy diets and physical inactivity. Consequently, integrated dietary strategies and actions are required to promote healthy ageing and target major causes of morbidity and mortality in senior populations. The promising field of precision nutrition is rising as a therapeutic approach that aims to design tailored dietary interventions to prevent and manage chronic diseases. Indeed, precision nutrition approaches contemplate the interindividual heterogeneity caused by genetic/epigenetic dissimilarities, individual facets such as age and gender, the lifestyle and environmental exposome diversity, microbiome variations, and singular behavioral/psychological features. On the other hand, the inclusion of potentially bioactive compounds and functional foods as promoters of healthy aging within personalised dietary patterns could be an effective strategy to delay the aging process and age-related chronic diseases. One of the main limitations of a dietary prescription is the lack of compliance, due to the complexity of the prescription itself and/or the lack of commitment of the individual. The inclusion of digital tools to empower and motivate individuals and to support them in the management of the dietary strategy could overcome this limitation. With this background, the general objective of this investigation is to design precision nutritional strategies based on the inclusion of functional foods and digital tools for preventing age-related chronic diseases in pre-senior and senior populations. Additionally, this study proposes alternative tools for cognitive assessments increasing the accessibility to cognitive assessment tools for this population as well as an innovative digital tool for cognitive stimulation which is personalized, monitored, and evidence-based.
Status | Completed |
Enrollment | 126 |
Est. completion date | December 23, 2020 |
Est. primary completion date | December 23, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: - Men and women aged 50-80 years - BMI >27 kg/m2 - One or more of the following risk factors: - Glucose =100 to =125 mg/dL or type 2 diabetes (independently of antidiabetic medication) - Hypertension (systolic blood pressure =140 mmHg or diastolic blood pressure =90 mmHg or under antihypertensive medication) - LDL-cholesterol =160 mg/dL independently of lipid-lowering therapy - HDL-cholesterol =40 mg/dL (men)/=50 mg/dL (women), independently of lipid-lowering therapy - Triglycerides =160 mg/dL independently of lipid-lowering therapy - Waist Circumference ?95 cm (men)/>82 cm (women), independently of lipid-lowering therapy - Sedentary behavior (AHA)* Exclusion Criteria: - Relevant functional or structural digestive abnormalities (malformations, angiodysplasia, active peptic ulcers, chronic inflammatory diseases, or malabsorption) - Endocrine disorders (hyperthyroidism or uncontrolled hypothyroidism) - Undergone surgical interventions with permanent sequelae (gastroduodenostomy) - Pharmacological treatments with immunosuppressants, cytotoxic agents, systemic corticosteroids, or other drugs that could potentially cause hepatic steatosis or alteration of liver tests - Active cancer in the last five years or under therapy - Weight loss =3 kg in the last three months - Instable drug therapy in the last three months - Severe psychiatric disorders - No autonomy - Inability to follow the diet (food allergies, intolerances) - Difficulties to follow scheduled visits - AHA Recommendations for Physical Activity in Adults: at least 150 minutes per week of moderate-intensity aerobic activity or 75 minutes per week of vigorous aerobic activity, or a combination of both, preferably spread throughout the week. |
Country | Name | City | State |
---|---|---|---|
Spain | Centre for Nutrition Research, University of Navarra | Pamplona | Navarra |
Lead Sponsor | Collaborator |
---|---|
Clinica Universidad de Navarra, Universidad de Navarra |
Spain,
Brooke, JB (1996). SUS - a quick and dirty usability scale. In: Usability Evaluation in Industry, Jordan, P, Thomas, B, Weerdmeester, B, and McLelland, I(eds), Taylor and Francis: London
de Toro-Martín J, Arsenault BJ, Després JP, Vohl MC. Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome. Nutrients. 2017 Aug 22;9(8). pii: E913. doi: 10.3390/nu9080913. Review. — View Citation
González-Muniesa P, Martínez JA. Precision Nutrition and Metabolic Syndrome Management. Nutrients. 2019 Oct 9;11(10). pii: E2411. doi: 10.3390/nu11102411. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline General Health Status at 3 Months | General health score encompassed twelve parameters, on a scale of 0 to 21, with higher scores indicating a worse overall health:
BMI Waist Circumference Glycosylated hemoglobin (HbA1C) Total cholesterol HDL-cholesterol LDL-cholesterol Triglycerides Uric acid Systolic Blood Pressure | Diastolic Blood Pressure Gastrointestinal Health (GSRT) Cognitive Function Extra negative point if reducing medication |
0 months and 3 months | |
Secondary | Change From Baseline Weight at 3 Months | Weight was measured by a digital scale | 0 months and 3 months | |
Secondary | Baseline height | Height was recorded using a wall-mounted stadiometer (Seca 220, Vogel & Halke, Germany). | 0 months | |
Secondary | Change From Baseline Body Mass Index at 3 Months | Body mass index was calculated using the standard formula: weight (kg)/height (m)2 | 0 months and 3 months | |
Secondary | Change From Baseline Fat Mass at 3 Months | Fat mass was measured by Bioelectrical impedance analysis (BIA, SC-330, Tanita) | 0 months and 3 months | |
Secondary | Change From Baseline Lean Mass at 3 Months | Lean mass was measured by Bioelectrical impedance analysis (BIA, SC-330, Tanita) | 0 months and 3 months | |
Secondary | Change From Baseline Waist Circumference at 3 Months | Waist Circumference was measured by with a tape measure | 0 months and 3 months | |
Secondary | Change From Baseline Hip Circumference at 3 Months | Hip Circumference was measured by with a tape measure | 0 months and 3 months | |
Secondary | Change From Baseline Systolic Blood Pressure at 3 Months | Systolic Blood Pressure was measured using an automatic monitor device (Intelli Sense. M6, OMRON Healthcare, Hoofdorp, the Netherlands) | 0 months and 3 months | |
Secondary | Change From Baseline Diastolic Blood Pressure at 3 Months | Diastolic Blood Pressure was measured using an automatic monitor device (Intelli Sense. M6, OMRON Healthcare, Hoofdorp, the Netherlands) | 0 months and 3 months | |
Secondary | Change From Baseline Serum Triglycerides at 3 Months | Triglycerides were measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Total Cholesterol at 3 Months | Total cholesterol was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum LDL-Cholesterol at 3 Months | LDL-cholesterol was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum HDL-Cholesterol at 3 Months | HDL-cholesterol was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Uric Acid at 3 Months | Uric acid was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Glucose at 3 Months | Glucose was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Insulin at 3 Months | Insulin was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Glycosylated hemoglobin (HbA1C) at 3 Months | Glycosylated hemoglobin (HbA1C) was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Aspartate Aminotransferase at 3 Months | Aspartate aminotransferase was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Alanine Aminotransferase at 3 Months | Alanine aminotransferase was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Serum Gamma-glutamyltransferase at 3 Months | Gamma glutamyltransferase was measured in fasting conditions | 0 months and 3 months | |
Secondary | Change From Baseline Physical Activity Level at 3 Months | Physical activity was measured by the International Physical Activity Questionnaire (IPAQ) | 0 months and 3 months | |
Secondary | Change From Baseline Dietary Intake at 3 Months | Dietary intake was measured by a 7-day recall | 0 months and 3 months | |
Secondary | Change From Baseline Mediterranean Diet Adherence at 3 Months | Mediterranean diet adherence was measured by the 14-Item Mediterranean Diet Assessment Tool | 0 months and 3 months | |
Secondary | Change From Baseline Health Status at 3 Months | Health status was measured by the SF-36 Health Survey | 0 months and 3 months | |
Secondary | Change From Baseline Gastrointestinal Symptoms at 3 Months | Gastrointestinal symptoms were measured by the gastrointestinal symptoms rating scale, GSRT | 0 months and 3 months | |
Secondary | Change From Baseline Sensory Perception of Precision Foods at 3 Months | Sensory perception of precision foods was measured by the sensory perception questionnaire | 1 month and 3 months | |
Secondary | Food Consumption of the Precision Foods | Food consumption of the precision foods was measured by a food consumption record | 1 month, 2 months and 3 months | |
Secondary | Change From Baseline Risk of Malnutrition at 3 Months | Risk of malnutrition was measured by the Mini Nutritional Assessment (MNA) questionnaire | 0 months and 3 months | |
Secondary | Change From Baseline Cognitive Impairment at 3 Months | Cognitive impairment was measured by the Mini-Mental State Examination (MMSE) questionnaire | 0 months and 3 months | |
Secondary | Change From Baseline Cognitive Function at 3 Months | Cognitive function was measured by the Guttmann NeuroPersonalTrainer platform | 0 months and 3 months | |
Secondary | Baseline Gut Microbiota Composition | Gut Microbiota Composition will be measured using OMNIgene.GUT kits from DNA Genotek | 0 months | |
Secondary | Usability of the digital tools | Usability will be measured using the System Usability Scale (SUS) | 3 months | |
Secondary | Baseline subjective hunger | Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived hunger before the experimental food intake | Baseline | |
Secondary | Postprandial subjective hunger | Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived hunger measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Baseline subjective fullness | Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived fullness before the experimental food intake | Baseline | |
Secondary | Postprandial subjective fullness | Visual analogue scale rating in a scale from 0 to 100 mm, for the quantification of the perceived fullness measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Baseline subjective satiety | Visual analogue scale rating in a scale from 0 to100 mm for the quantification of the perceived satiety before the experimental food intake. | Baseline | |
Secondary | Postprandial subjective satiety | Visual analogue scale rating in a scale from 0 to100 mm for the quantification of the perceived satiety measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake | Up to 120 minutes | |
Secondary | Baseline subjective desire to eat | Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived desire to eat before the experimental food intake at baseline. | Baseline | |
Secondary | Postprandial subjective desire to eat | Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived desire to eat measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake | Up to 120 minutes | |
Secondary | Baseline subjective thirst | Visual analogue scale rating in a scale from 0 to 100 mm for the quantification of the perceived thirst before the experimental food intake at baseline | Baseline | |
Secondary | Postprandial subjective thirst | Visual analogue scale ratings in a scale from 0 to 100 mm for the quantification the perceived thirst measured at 15, 30, 45, 60, 90 and 120 minutes after experimental food intake | Up to 120 minutes | |
Secondary | Baseline blood glucose concentration | Blood glucose concentration before experimental food intake | Baseline | |
Secondary | Baseline blood insulin concentration | Blood insulin concentration before experimental food intake | Baseline | |
Secondary | Incremental area under the curve (iAUC) for glucose | The incremental area under the curve (AUCi) for glucose was calculated via the geometric sums of the areas of the triangles and trapezoids above the fasting glucose concentration over a 2-h period | 0,15,30,45,60,90,120 | |
Secondary | Incremental area under the curve (iAUC) for insulin | The incremental area under the curve (AUCi) for insulin was calculated via the geometric sums of the areas of the triangles and trapezoids above the fasting insulin concentration over a 2-h period | 0,15,30,45,60,90,120 | |
Secondary | Baseline blood high density lipoprotein cholesterol (HDL) concentration | Blood high density lipoprotein cholesterol (HDL) concentration before experimental food intake | Baseline | |
Secondary | Baseline blood low density lipoprotein cholesterol (LDL) concentration | Blood low density lipoprotein cholesterol (LDL) concentration before experimental food intake | Baseline | |
Secondary | Baseline blood triglyceride concentration | Blood triglyceride concentration before experimental food intake | Baseline | |
Secondary | Postprandial blood glucose concentration | Blood glucose concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Postprandial blood insulin concentration | Blood insulin concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Postprandial blood total cholesterol concentration | Blood total cholesterol concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Postprandial blood high density lipoprotein cholesterol (HDL) concentration | Blood high density lipoprotein cholesterol (HDL) concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Postprandial blood low density lipoprotein cholesterol (LDL) concentration | Blood low density lipoprotein cholesterol (LDL) concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes | |
Secondary | Postprandial blood triglyceride concentration | Blood triglyceride concentration measured at 15, 30, 45, 60, 90 and 120 minutes after the experimental food intake | Up to 120 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013163 -
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03843424 -
Treatment Efforts Addressing Child Weight Management by Unifying Patients, Parents & Providers
|
N/A | |
Not yet recruiting |
NCT06360536 -
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
|
N/A | |
Not yet recruiting |
NCT05997576 -
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
|
Phase 3 | |
Recruiting |
NCT04763291 -
Cardiovascular and InflammAging Study
|
N/A | |
Active, not recruiting |
NCT04399460 -
The Effects of Long-term Consumption of Full-fat Dairy Products on Satiety, Body Weight and Glycemic Control
|
N/A | |
Completed |
NCT04451824 -
Examination of Circumferential Reduction
|
N/A | |
Completed |
NCT04110717 -
Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight
|
N/A | |
Completed |
NCT05561855 -
T2DM Intensity Lifestyle Intervention
|
N/A | |
Active, not recruiting |
NCT04100200 -
Berries, Inflammation, and Gut Microbiome
|
N/A | |
Recruiting |
NCT06125964 -
eMOTION Formative Study
|
N/A | |
Recruiting |
NCT06087822 -
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
|
N/A | |
Active, not recruiting |
NCT04328233 -
Impact of Time-Restricted Eating on Metabolic Homeostasis, Inflammation and Oxidative Stress in Metabolic Syndrome
|
N/A | |
Completed |
NCT06091761 -
Thread Embedding Acupuncture Combined With Auricular Acupuncture for Overweight and Obesity
|
N/A | |
Completed |
NCT04894344 -
Education to Decrease in Sodium Intake Evaluated With 24 Hour Urinary Sodium Excretion (RCT)
|
N/A | |
Completed |
NCT05713461 -
Physical Exercise in Obesity for Health and Quality of Life.
|
N/A | |
Not yet recruiting |
NCT06054698 -
Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects
|
Phase 2 | |
Not yet recruiting |
NCT02823912 -
Capsaicin Effect on Cytokines Profile in Dyslipidemia
|
Phase 2/Phase 3 | |
Completed |
NCT05104151 -
Efficacy of a Nutritive Bar, in Reduction of Weight, Body Fat and Control of Appetite
|
N/A | |
Enrolling by invitation |
NCT06092632 -
Efficacy of Pigmented Rice on Reducing Cardiometabolic Risk Factors Among Filipino Adults
|
N/A |